Pfizer win most probable outcome in ATTR-CM Patent Case
Summary
A court case between Pfizer (PFE) and generic drug manufacturers, which will determine control of the $16.5 billion-plus Transthyretin amyloid cardiomyopathy
Description
A court case between Pfizer (PFE) and generic drug manufacturers, which will determine control of the $16.5 billion-plus Transthyretin amyloid cardiomyopathy
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source